drugset
drugset / Trial / NCT05623189

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

NCT05623189 ↗

Phase 2 Completed 218 enrolled HighTide Biopharma Pty Ltd
RandomizedSequentialQuadruple-blindTreatment

Summary

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.

Timeline

Start
2022-12-27
Primary completion
2025-04-30
Completion
2025-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject berberine ursodeoxycholate Small molecule 1250 mg —

Indications

metabolic dysfunction-associated steatohepatitis type 2 diabetes mellitus